Last updated on March 2020

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Brief description of study

The purpose of the trial is to evaluate the safety of GEN1046 in patients with malignant solid tumors

Detailed Study Description

The trial is an open-label, multi-center safety trial of GEN1046. The trial consists of two parts, a dose escalation part (phase 1, first-in-human (FIH) and an expansion part (phase 2a)). The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been determined.

Clinical Study Identifier: NCT03917381

Find a site near you

Start Over